Evidence map›Paper›PMID 25566190›Full record

ArticleFrontiers in endocrinology2014

Evolution of hepatic steatosis to fibrosis and adenoma formation in liver-specific growth hormone receptor knockout mice.

Yong Fan, Xin Fang, Asako Tajima, Xuehui Geng, Sarangarajan Ranganathan, Henry Dong, Massimo Trucco, Mark A Sperling

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Growth hormone receptor gene disruption.Vitamins and hormones · 2023
    Article
  8. Article
  9. Mechanism ofNutrients · 2022
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yong FanInstitute of Cellular Therapeutics, Allegheny Health Network , Pittsburgh, PA , USA ; Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
Xin FangInstitute of Cellular Therapeutics, Allegheny Health Network , Pittsburgh, PA , USA ; Department of Pediatrics, Fujian Medical University Union Hospital , Fuzhou , China.
Asako TajimaInstitute of Cellular Therapeutics, Allegheny Health Network , Pittsburgh, PA , USA ; Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
Xuehui GengDivision of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
Sarangarajan RanganathanDepartment of Pathology, Children's Hospital of Pittsburgh of UPMC , Pittsburgh, PA , USA.
Henry DongDivision of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
Massimo TruccoInstitute of Cellular Therapeutics, Allegheny Health Network , Pittsburgh, PA , USA ; Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
Mark A SperlingDivision of Endocrinology, Department of Pediatrics, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
University of Pittsburgh · USAllegheny Health Network · USChildren's Hospital of Pittsburgh · US

Funding

Fox01 in Beta-Cell CompensationR01DK098437 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DONG, HENGJIANG HENRY · 2014 to 2017
$1.4M
NIDDK NIH HHS R01 DK098437
6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver diseases closely associated with obesity and insulin resistance; deficient growth hormone (GH) action in liver has been implicated as a mechanism. Here, we investigated the evolution of NAFLD in aged mice with liver-specific GHR deletion.

methodsWe examined glucose tolerance, insulin responsiveness, and lipid profiles in aged male mice (44-50 weeks) with GHRLD. We performed proteomics analysis, pathway-based Superarray assay, as well as quantitative RT-PCR to gain molecular insight into the mechanism(s) of GHR-deficiency-mediated NAFLD. In addition, we examined the pathological changes of livers of aged GHRLD male mice.

resultsThe biochemical profile was consistent with that of the metabolic syndrome: abnormal glucose tolerance, impaired insulin secretion, and hyperlipidemia. RT-qPCR analysis of key markers of inflammation revealed a three- to fivefold increase in TNFα and CCL3, confirming the presence of inflammation. Expression of fibrotic markers (e.g., Col1A2 and Col3A1) was significantly increased, together with a two- to threefold increase in TGFβ transcripts. Proteomics analyses showed a marked decrease of Mup1 and Selenbp2. In addition, pathway-analysis showed that the expression of cell cycle and growth relevant genes (i.e., Ccnd1, Socs2, Socs3, and Egfr) were markedly affected in GHRLD liver. Microscopic analyses (H&E) of GHRLD livers revealed the presence of hepatic adenomas of different stages of malignancy.

conclusionAbrogation of GH signaling in male liver leads to metabolic syndrome, hepatic steatosis, increased inflammation and fibrosis, and development of hepatic tumor. Since obesity, a common precursor of NAFLD, is a state of deficient GH secretion and action, the GHRLD model could be used to unravel the contribution of compromised hepatic GH signaling in these pathological processes, and help to identify potential targets for intervention.

Indexed as

growth hormone receptorhepatic steatosishepatocellular adenomaNAFLD

Identifiers

PMID25566190
PMCPMC4270248
OpenAlexW2032920195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.